Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 89 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Precigen Inc | PGEN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.42 | 07:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.42 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 89 | - | 0.8354 - 1.8799 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:08:40 | 89 | $ 1.45 | USD |
Precigen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 353.47M | 248.92M | - | 6.23M | -95.9M | -0.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Precigen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PGEN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.30 | 1.45 | 1.28 | 1.36 | 817,475 | 0.12 | 9.23% |
| 1 Month | 1.43 | 1.485 | 1.28 | 1.39 | 769,268 | -0.01 | -0.70% |
| 3 Months | 1.38 | 1.785 | 1.28 | 1.46 | 991,041 | 0.04 | 2.90% |
| 6 Months | 1.10 | 1.785 | 0.8354 | 1.30 | 1,216,477 | 0.32 | 29.09% |
| 1 Year | 1.15 | 1.8799 | 0.8354 | 1.33 | 1,291,006 | 0.27 | 23.48% |
| 3 Years | 8.12 | 8.72 | 0.805 | 2.42 | 1,367,860 | -6.70 | -82.51% |
| 5 Years | 5.13 | 11.10 | 0.805 | 3.44 | 1,405,422 | -3.71 | -72.32% |
Precigen Description
| Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals; Exemplar, and Trans Ova. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. |
